Figure 8 | Scientific Reports

Figure 8

From: Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib

Figure 8

Pyrazinib (P3) does not alter T cell viability. The effect of Pyrazinib (P3) on Jurkat cell viability was assessed by flow cytometry. (A) Representive flow plot of utreated and Pyrazinib (P3) treated jurkat cells. The percentage of (B) live (C) early apoptotic (D) late apoptotic and (E) necrotic jurkat cells following 24 or 48 h treatment with media only, 0.1% DMSO control of 0.1, 1, 5 or 10 µM of Pyrazinib (P3), (n = 3). Paired t-tests.

Back to article page